Please assess the completion status of the following clinical trial:

Trial Title: Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 2 to 75 years~* Subjects with primary humoral immunodeficiency, namely with a diagnosis of: CVID (Common Variable Immunodeficiency) as defined by PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies) or XLA (X-linked Agammaglobulinemia)~* Written informed consent~Exclusion Criteria:~* Newly diagnosed PID~* Evidence of an active serious infection at the time of screening (i.e., but not limited to: bacteremia/septicemia, pneumonia, fungal osteomyelitis)~* Malignancies of lymphoid cells such as lymphocytic leukemia, Non-Hodgkin's lymphoma and immunodeficiency with thymoma~* Known hyperprolinemia~* Hypoalbuminemia, protein-losing enteropathies, and any proteinuria~* Allergic reactions to immunoglobulins or other blood products~* Known antibodies to Immunoglobulin A (IgA)~* The subject is receiving steroids (oral and parenteral, daily ≥ 0.15 mg of prednisone equivalent/kg/day) or other systemic immunosuppressants~* Female who is pregnant, breast feeding or planning a pregnancy during the course of the study~* Participation in a study with an investigational product other than (IVIG) within 1 month prior to enrollment~* A positive result at screening on any of the following viral markers: Human Immunodeficiency Virus (HIV), Hepatitis C virus (HCV) and Hepatitis B virus (HBV)~* Aspartate aminotransferase (ASAT) or Alanine aminotransferase (ALAT) concentration \> 2.5 times the upper normal limit (UNL)~* Creatinine concentration \> 1.5 times the UNL~* Any condition that is likely to interfere with evaluation of the study drug or satisfactory conduct of the trial

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IgPro20 (Type: EXPERIMENTAL): Human Normal Immunoglobulin for Subcutaneous Administration (IgPro20) is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).